At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)
In Brief
A Phase 2 clinical trial evaluating Placebo and LX9211 for Postherpetic Neuralgia. Completed, enrolled 79 participants across 32 sites in 3 countries.
Detailed Summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia
CountriesCzechia, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionNov 2022
Study CompletionDec 2022
TodayJul 2026
First PostedDec 10, 2020
Enrollment StartDec 10, 2020
Primary CompletionNov 18, 2022
Study CompletionDec 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.6 years ago
Interventions
Placebodrug
LX9211 matching-placebo, tablets will be administered orally.
LX9211drug
LX9211 tablets will be administered orally.